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Even though the bulk of experimental evidence has reported that
aberrations of the tumour suppressor gene p53 play a critical role
in ovarian carcinogenesis and progression (Marks et al, 1991;
Kohler et al, 1993, Kupryjanczyk et al, 1993, 1994), we are still far
from defining the potential usefulness of p53 assessment in the
clinical management of ovarian cancer patients, especially in
terms of prediction of response to chemotherapy and identification
of patients at high versus low risk of progression, recurrence and
death by disease (Marks et al, 1991; Hartmann et al, 1994;
Henriksen et al, 1994; Klemi et al, 1995; Levesque et al, 1995; van
der Zee et al, 1995; Diebold et al, 1996; Herod et al, 1996; Reles et
al, 1996; Righetti et al, 1996; Buttitta et al, 1997; Dong et al, 1997;
Geisler et al, 1997; Rohlke et al, 1997; Marx et al, 1998).
The difficulties, not exclusively limited to p53, in translating the
information of biological factors from ‘in vitro’ models to the clin-
ical setting in ovarian carcinoma, might come from the heteroge-
neous population of ovarian cancer patients examined in different
studies; in particular, (a) the achievement of optimal tumour resec-
tion is differently defined, (b) there is no uniformity in chemo-
therapeutic regimens, and (c) response to chemotherapy, which
is sometimes difficult to define given the high frequency of
unmeasurable lesions, has been heterogeneously considered and
analysed. The aim of this study was to investigate the association
of p53 status with primary cytoreduction, response to
chemotherapy and outcome in primary ovarian cancer patients.
The study was conducted by analysing distinct homogeneous
groups of patients, defined according to the type of primary
surgery, extent of cytoreduction, criteria of response to
chemotherapy and follow-up procedures, in order to minimize
possible bias represented by inaccurate or unclearly defined selec-
tion of patients. Moreover, all surgical procedures, chemothera-
peutic treatments and follow-up studies were performed by the
same gynaecological oncology institution. For this study, we
decided to utilize the immunohistochemical approach, since
immunohistochemical results have been reported to be highly
correlated with mutational analysis data (Marks et al, 1991;
Bodner et al, 1992; Eccles et al, 1992; Kupryjanczyk et al, 1993)
and immunohistochemistry is more suitable for routine utilization
if a practical application of p53 assessment is to be achieved. The
monoclonal antibody DO-7, which recognizes both the wild-type
and the mutated form of p53 and has been shown to be the most
suitable antibody for p53 assessment (Righetti et al, 1996) was
used.
PATIENTS AND METHODS
This study was conducted on 168 primary untreated ovarian
cancer patients admitted to the Department of Gynecological
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Clinico-pathologic characteristics of our patient population are
summarized in Table 1. The flow-chart of our patient population
subsets is shown in Figure 1. Since the study was aimed to assess
the possible clinical role of p53 status in terms of association with
ovarian tumour cytoreduction, response to chemotherapy and
survival, most of the analyses were performed in the group of
stage III–IV patients.
One hundred and thirty-six stage III–IV ovarian cancer patients
underwent explorative laparotomy. Even though several cut-off
values of residual tumour volume have been proposed, it has been
reported that gradual gradations of residual disease can affect
ovarian cancer patient prognosis (Potter et al 1991; Bristow et al,
1996; Heintz, 1996). Our patient population was divided into three
subgroups according to the extent of residual disease: group A
included 89 patients (65.5%) who were optimally (absent/micro-
scopic) or sub-optimally (less than 2 cm residual disease) cyto-
reduced; group B included 15 (11%) patients with 2–5 cm residual
disease; and Group C was constituted of 32 (23.5%) cases consid-
ered unresectable at the time of laparotomy and submitted only to
multiple biopsies.
The 104 patients in which a measurable residual disease volume
was left (group A and B) were considered for chemotherapy
response assessment. Two to 3 weeks after surgery, four to six
cycles of cisplatin-based chemotherapy (total cisplatin dose at
least 400 mg m–2) were administered to 102 (98%) patients (two
patients were lost to follow-up). In only ten out of 102 patients
(9.9%) the chemotherapy regimen included Taxol, making
the separate statistical analysis of this subgroup unreliable.
Gynaecological examination, abdominopelvic ultrasonography,
CA-125 assay and radiological investigations, if necessary, were
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Table 1 Clinico-pathological characteristics of ovarian cancer patients and
distribution of p53-positivity
p53-positive cases
Characteristics No. (%) No. (%) P-valuea
of patients of patients
All cases 168 84 (50)
LMP tumours 6 (3.5) 0
Carcinomas 162 (96.5) 84 (52)
Age (years)
≤ 60 110 (68) 55 (50) 0.50
> 60 52 (32) 29 (56)
Histotype
Serous 108 (66) 56 (52)
Mucinous 6 (4) 1 (17) 0.26
Endometrioid 30 (19) 17 (57)
Undifferentiated 14 (8.5) 9 (64)
Other 4 (2.5) 1 (25)
FIGO stage
I 21 (13) 5 (24)
II 5 (3) 1 (20) 0.0022b
III 107 (66) 60 (56)
IV 29 (18) 18 (62)
Grade of differentiation
G1 16 (10) 4 (25) 0.0038c
G2 28 (17) 10 (36)
G3 104 (64) 61 (59)
NA 14 (9) –
Ascites
No 71 (44) 32 (45) 0.15
Yes 91 (56) 51 (57)
aCalculated by Fisher’s exact test for proportion; bstage III–IV versus stage
I–II; cgrade 3 versus grade 1–2.
6 (3.5%) Borderline ovarian tumours
21 (12.5%) Stage I patients
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Figure 1 Flow chart events of our patient population studyperformed monthly for the clinical assessment of response, which
was recorded according to World Health Organization criteria
(WHO, 1979).
Seven patients were not assessed for response to chemotherapy
since they were lost to follow-up. Approximately 28 days after the
last course (range 3–6 weeks), 53 patients out of 78 clinical
responders underwent second-look laparoscopy or, in laparoscopy-
negative cases, second-look laparotomy for the assessment of
pathologic response. Second-look procedures were not performed
in 25 patients because of patient refusal (n = 17) and severe drug
toxicity (n = 8).
Peritoneal washings, careful inspection of the abdominal cavity
and biopsy of all suspicious lesions were performed; in the case of
no evidence of disease, at least 20 random biopsies were taken.
Pathologic complete responders (n = 39) received either no further
therapy or alternative therapies and entered follow-up procedures.
Pathological partial responders (n = 6) and patients who showed
pathologic stabilization/progression of disease (n = 8) or clinically
unresponsive to first-line treatment (n = 17) were treated according
to second-line chemotherapy regimens.
Unresectable patients (Group C) were submitted to two or three
cycles of cisplatin-based chemotherapy before attempting a second
cytoreductive effort which was limited to patients who showed
clinical response to primary treatment (n = 25).
Immunohistochemical analysis
Immunohistochemical analysis of the p53 protein was performed
on 168 ovarian carcinomas, using the avidin–biotin–peroxidase
complex method (ABC) (Dako, Carpinteria, CA, USA) and the
specific mouse monoclonal antibody for p53 (DO-7, Dako,
Carpinteria, CA, USA) which recognizes both the wild-type and
the mutant form of p53 protein.
Five-micrometer sections were dewaxed in xylene, rehydrated
in descending concentration of alcohol down to 80%, washed in
tap and distilled water, and then treated with 0.3% hydrogen
peroxide in methanol for 25 min to remove endogenous peroxi-
dase activity. Sections were washed in Tris-buffered saline solu-
tion (TBS) (pH 7.6) and then microwave-treated (two cycles of
5 min) in 10 mM trisodium citrate buffer solution (pH 6.0). After
three washes in TBS, sections were incubated with normal serum
as blocking reagent to minimize non-specific binding.
A 1:100 dilution of the specific mouse monoclonal antibody to
p53 protein (DO-7) was applied for 60 min at room temperature.
The sections were then incubated with the biotinylated goat anti-
mouse IgG and with avidin–biotin–peroxidase complex for 10 min
at room temperature. Finally, the sections were washed in TBS,
stained by incubation with 3-amino-9-ethylcarbazole (AEC)
(Dako, Carpinteria, CA, USA) for 10–20 min and then counter-
stained with haematoxylin. Fetal calf serum (Dako, Carpinteria,
CA, USA) was used as a negative control.
The sections were examined independently by two observers
(MM and AF) by means of light-microscopic examination and
scored according to the intensity of staining and proportion of cells
stained. In case of disagreement, the sections were reviewed on a
two-headed microscope (Laborlux-S, Leitz), in order to reach a
consensus. In detail, the cases were scored as negative when no
staining was observed. When the positivity was observed in more
than 1% of tumour cells (which corresponds to the median value),
the cases were scored as positive.
The scoring of the immunohistochemical data was determined
without any knowledge of the clinico-pathological parameters or
of the follow-up data.
Statistical analysis
Fisher’s exact test for proportion was used to analyse the distribution
of p53-positivity according to clinico-pathological characteristics.
The association of clinico-pathological parameters and p53-
status with response to chemotherapy and cytoreduction was
assessed in a multivariate model by the stepwise logistic regres-
sion (Cox, 1970). This model enabled us to predict the probability
of a particular outcome to take place, after combining the informa-
tions deriving from several parameters. In this model, the 
b-estimate corresponds to the ‘regression coefficient’ for each
variable, and the c2 value indicates the strength of the evidence
against the null hypothesis of no association between a specific
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Figure 2 p53 nuclear immunostaining in ovarian cancer tissue. (A) Original
magnification 40´. (B) Original magnification 100´variable and the outcome. The probability of obtaining a c2 value
greater than above is known as P-value.
All medians and life-tables were computed using the product-
limit estimate and the curves were examined by means of the
log-rank test (Mantel 1966). Time to progression and overall
survival were calculated from the day of the first surgery to the
date of clinical or pathological progression or death. All survival
analyses were performed using SOLO Statistical Software (BMDP
Statistical Software Inc., Los Angeles, CA, USA).
RESULTS
Figure 2 shows a representative example of p53 immunohisto-
chemical analysis in ovarian cancer tissue. Nuclear immunos-
taining was evident in many cancer cells, whereas the stromal
component was unreactive.
Table 1 shows the distribution of p53-positivity in six low
malignant potential (LMP) tumours and 162 primary ovarian
carcinomas. All LMP tumours were p53-negative, while the
percentage of p53 nuclear positivity was 52% in the group of
malignant tumours.
In Table 1 the distribution of p53-positivity according to
clinico-pathological characteristics is shown. p53-positivity was
not distributed differently according to patient age and histotype.
On the other hand, a higher percentage of p53 nuclear positivity
was observed in patients with advanced stage of disease than in
stage I–II (57% vs 23% respectively; P = 0.0022). Similarly,
poorly differentiated tumours were more frequently p53-positive
than well/moderately differentiated ones (59% vs 32% respetively;
P = 0.0038). No association between p53 status and absence/
presence of ascites was found.
The association of clinico-pathological features and p53 status
with primary cytoreduction, response to chemotherapy and
survival was focused on the subgroup of stage III–IV patients
(n = 136), as pointed out in Materials and Methods.
In order to investigate the possible independent role of clinico-
pathological features and p53 status as parameters associated with
primary cytoreduction in the multivariate model, the dichotomiza-
tion of patients according to the extent of residual tumour volume
had to be performed. Analyses were conducted by comparing
group A+B versus C, or alternatively group A versus group B+C.
Since similar results were obtained in both comparisons, we
decided to show the analysis comparing subgroup of patients with
tumour volume < 2 cm (group A) versus ³ 2 cm (group B+C)
(Table 2), due to the reason that the value of 2-cm residual disease
is the most frequently used cut-off for primary debulking surgery
likely to have a relevant impact on patients’ survival.
A higher percentage of stage III with respect to stage IV cases
was observed in the group A (89% vs 11% respectively; P =
0.0002). Moreover, a trend towards a higher percentage of poorly
differentiated compared to well/moderately differentiated tumours
in group B+C was observed (P = 0.068). Table 2 also shows that a
higher percentage of p53-positive than p53-negative cases was
found in the group B+C (68% vs 32% respectively; P = 0.07).
Moreover, within group A, no differences in p53-positivity
according to the amount of residual tumour was found: p53-posi-
tivity was observed in 14 out of 33 patients (42%) with absent or
microscopic residual tumour and in 32 out of 56 patients (57%)
with < 2-cm residual tumour (data not shown).
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Table 2 Distribution of clinico-pathological parameters and p53 status
according to residual tumour volume in stage III–IV ovarian cancer patients
Group A Group B+C
Characteristics No. (%) No. (%) P-valuea
of patients of patients
All cases 89 47
Age (years)
≤60 61 (68.5) 30 (64) 0.70
> 60 28 (31.5) 17 (36)
Histotype
Serous 61 (68.5) 31 (66)
Mucinous 2 (2) 1 (2)
Endometrioid 20 (22) 6 (13) 0.20b
Undifferentiated 5 (5.5) 8 (17)
Other 1 (1) 1 (2)
FIGO stage
III 79 (89) 28 (59.5) 0.0002
IV 10 (11) 19 (40.5)
Grade of differentiation
G1-G2 24 (28.5) 5 (12.5) 0.068
G3 60 (71.5) 35 (87.5)
Ascites
No 35 (40) 13 (28) 0.22
Yes 54 (60) 34 (72)
p53 status
Negative 43 (48) 15 (32) 0.07
Positive 46 (52) 32 (68)
aCalculated by Fisher’s exact test for proportion; bcalculated by c2 test
(not accurate).
Table 3 Distribution of clinico-pathological parameters and p53 status
according to pathological response to chemotherapy in stage III–IV ovarian
cancer patients
Pathological Pathological
complete response partial/no change
response
Characteristics No. (%) No. (%) P-valuea
of patients of patients
All cases 39 14
Age (years)
≤ 60 36 (92) 11 (78.5) 0.32
> 60 3 (8) 3 (21.5)
Histotype
Serous 28 (72) 9 (64) 0.68
Endometrioid 6 (15) 4 (29)
Undifferentiated 4 (10) 1 (7)
Other 1 (3) 0
FIGO stage
III 36 (92) 8 (57) 0.006
IV 3 (8) 6 (43)
Grade of differentiation
G1–G2 9 (25) 6 (46) 0.17
G3 27 (75) 7 (54)
Ascites
No 15 (38) 6 (43) 1.0
Yes 23 (62) 8 (57)
Residual tumour
Group A 36 (92) 9 (64) 0.023
Group B 3 (8) 5 (36)
p53 status
Negative 21 (54) 2 (14) 0.012
Positive 18 (46) 12 (86)
aCalculated by Fisher’s exact test for proportion.The multivariate analysis used to investigate the association of
FIGO stage, grade and p53 status with primary cytoreduction was
carried out. Stage IV disease was demonstrated to be strongly
associated with poor chance of primary cytoreduction (b-estimate:
1.79; c2: 13.66; P-value: 0.0002) and p53-positivity also main-
tained the trend to be associated with low possibility of cyto-
reduction (b-estimate: 0.80; c2: 3.38; P-value: 0.065). The c2 of
the model was 19.12 (2 degrees of freedom) with a P-value
of 0.0001.
The possible correlation of clinico-pathological characteristics
as well as p53 status with response to chemotherapy was analysed
in group A and B patients, after dichotomizing type of response
into pathological complete response (n = 39) versus pathological
partial or no response to treatment (n = 14) plus clinical progres-
sion (n = 17). No association between p53 status and response to
chemotherapy was observed (data not shown). However, when the
analysis was performed only in patients who underwent patholog-
ical assessment of response (n = 53) (Table 3), patients who did not
respond to chemotherapy were more frequently p53-positive than
p53-negative (86% vs 14% respectively; P = 0.012). Moreover,
stage III patients were more likely to respond to treatment than
stage IV cases (92% vs 8% respectively; P = 0.006). Finally, group
A patients were found to have a higher chance of response than
group B patients (92% vs 8% respectively; P = 0.023). Age,
histotype, grade of differentiation and presence/absence of ascites
did not show any association with response to chemotherapy.
The multivariate analysis, including the variables significantly
associated with response to chemotherapy in univariate analysis,
showed that FIGO stage (b-estimate: 2.41; c2: 6.58; P-value: 0.01)
and p53 expression (b-estimate: 2.13; c2: 5.22; P-value: 0.022)
were independently correlated with pathological response to
chemotherapy. The c2 of the model was 15.04 (2 degrees of
freedom) with a P-value of 0.0005.
In the group of unresectable patients (group C), assessment of
response to 2–3 cycles of chemotherapy was evaluated on 29/32
cases (three patients died before starting chemotherapy). Nine
patients who did not show any clinical benefit from treatment or
proved not to be susceptible to interval debulking surgery (IDS)
were compared to patients in which IDS was achievable (n = 20).
Neither the clinico-pathological parameters nor the p53 status
were shown to be differently distributed in these two groups (data
not shown).
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Figure 3 Survival analysis according to p53 status in advanced ovarian cancer patients. (A) Time to progression in group A; (B) time to progression in group
B+C; (C) overall survival in group A; (D) overall survival in group B+CSurvival analysis
Survival analysis was focused on the more homogeneous group of
stage III–IV ovarian cancer patients. The median follow-up period
was 22 months (range 1–141 months), during which we observed
80 progressions and 61 deaths of disease. The median time to
progression was 15 months (range 1–126 months). Time to
progression (Figure 3 A, B) and overall survival rates (Figure 3 C,
D) were not different in p53-positive versus p53-negative patients.
Survival analysis gave superimposable results when performed
on the entire population (data not shown).
DISCUSSION
At present, few studies have investigated the association of p53
status with primary cytoreduction in ovarian carcinoma. In stage
III–IV ovarian cancer patients, a higher percentage of p53-posi-
tivity was found in the group of patients with a larger extent of
residual disease. The risk that the feasibility of tumour reduction,
and the extent of cytoreduction might be influenced by the skills
of different surgeons or involvement of non-gynaecological
oncology surgeons is minimal, since all cases analysed were
submitted to explorative laparotomies and cytoreductive efforts by
the same surgical team. Moreover, the association of p53-posi-
tivity with advanced stage of disease or other clinical parameters
of tumour aggressiveness appears not to be the entire explanation
to our findings, since FIGO stage as well as p53 status were found
to be independently associated with ovarian tumour cytoreduction
as determined by multivariate analysis.
A common finding of gynaecological oncology surgeons is that,
besides the simple bulky extension of tumour mass, the extent to
which tumour permeates and invades crucial anatomic structures
like mesenteries and vascular supplies could heavily influence the
possibility of successful tumour debulking. In this context, the
observation by Bouvet et al (1998) that the reintroduction of the
wild-type p53 gene into human colon cancer cells is associated
with the inhibition of neo-vascularization in vivo seems quite
intriguing, suggesting that abnormal p53 expression could also be
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Table 4 Studies analysing the association between p53 status, response to chemotherapy and prognosis in ovarian cancer patients
Author Antibody No. No. of No. of Response No. of Association Multivariate Association with Multivariate
(year) (sections) of patients stage I–II optimally to pathological with poor analysis for poor survival analysis for
debulked chemotherapy complete response response (population analysed) survival
response
Marks et al PAb 1801 107a 15 15b – – – – NS –
(1991) (frozen)
Hartmann et al PAb 1801 284 56 – 238 78 NS – Direct (P = 0.04) NS
(1994) (paraffin) all stages
Henriksen et al PAb 1801 55 26 31c – – – – Direct –
(1994) (frozen) all stages
Klemi et al n.d. 136 47 68d – – – – Direct (P = 0.002) Direct
(1995) (paraffin) all stages
Levesque et al Pab 240 90 27 34e – – – – Direct (P = 0.06) NS
(1995) (ELISA) all stages
van der Zee et al CM1 89f 20 50d 70 21 NSg – Direct (P < 0.001) NS
(1995) (paraffin) stage III–IV
Diebold et al DO-1 148h 71 – – – – – Direct Direct
(1996) (paraffin) all stages and LMP




Reles et al BP53-12-1, 179 74 145d – – – – NS –
(1996) DO-1
(paraffin)
Righetti et al DO-7 33 – 8d 32 13i Direct – – –
(1996) (paraffin)
Buttitta et al PAb 1801 53 14 – 33 7 Direct – Directm –
(1997) (frozen) not clearly specified
Dong et al DO-7 141n 47 – 44 – Directo – Direct (P = 0.003) NS
(1997) (paraffin) all stages
Geisler et al PAb 1801 83 16 56b – – – – Directm (P = 0.001) Directp
(1997) (frozen) not specified
Rohlke et al Ab-6 104q 28 – 50 35 NS – Direct Direct
(1997) (paraffin) all stages, stage III–IV
Marx et al DO-7 187 40 5r – – – – Direct –
(1998) (paraffin) all stages
Current study DO-7 162 26 89d,s 95 39 Directt Direct NS –
(paraffin) stage III–IV
a38 pretreated patients; bless than 1 cm; cless than 2 cm; d55 patients received surgery in the referring hospital; enumber of pathologically complete responses
not specified; fP = 0.014, when complete response vs other response types was compared; gresidual tumour = absent; all stages included; hLMP tumours
included (n = 30); itreatment and subgroups not clearly defined; lpathological response (n = 12); mKaplan and Meier analysis not performed; nincluding 16 LMP;
oresponse was clinically defined; poor response was associated with negative or high p53 expression; plogistic regression analysis was used; q89 out 136 stage
III–IV patients; rin pathologically verified response.involved in the deregulation of neo-angiogenesis and/or tumour
angiotropism.
Even though the statistical significance of our finding is appar-
ently not strong enough to support the clinical usefulness of p53
status assessment in predicting the feasibility of primary tumour
cytoreduction, it is conceivable that tumour susceptibility to be
cytoreduced may also be influenced by intrinsic biological charac-
teristics of aggressiveness, thus emphasizing the importance of
simultaneous investigation of multiple biological factors as
possible predictors of successful tumour debulking.
We observed that a higher percentage of p53-positive cases was
associated with a poor chance of response to treatment since
patients who did not respond to chemotherapy were more
frequently p53-positive. On the other hand, a certain number of
cases who achieved pathological response to treatment were found
to show p53 nuclear positivity. This findings, which confirms
previous data by Righetti et al (1996), could be explained by the
fact that wild-type p53 protein can accumulate without detectable
mutations, and this may be due to altered regulation of p53
expression or presence of p53-interacting and -stabilizing proteins
(Momand et al, 1992).
Several in vitro observations (Brown et al, 1993; Gjerset et al,
1993; Perego et al, 1996) have suggested an involvement of
p53 protein in determining the response to cisplatin-based
chemotherapy. Results of previous reports dealing with the associ-
ation of p53 with response to chemotherapy in ovarian carcinoma
patients are conflicting (Table 4). Our results, confirmed by multi-
variate analysis taking into account other relevant clinico-patho-
logical parameters, are in agreement with the observations of
previous studies (Righetti et al, 1996; Buttitta et al, 1997; Dong et
al, 1997) and some recent findings (Katsaros et al, 1998). In the
study by van der Zee et al (1995) p53-positive cases have been
reported not to be distributed differently according to type of
response. However, after dichotomizing complete response versus
no response, a statistically significant higher percentage of p53-
positivity was found to be associated with a poor chance of
response to treatment. Therefore, five out of eight studies demon-
strated that p53 expression is associated with response to cisplatin-
based chemotherapy. Moreover, a significant dose–response effect
has been recently reported in p53-negative versus p53-positive
ovarian cancer patients (Marx et al, 1998).
Our finding that p53 status fail to be correlated with response to
chemotherapy when patients experiencing clinical progression
were included in the analysis, seemed quite surprising. A possible
explanation of this observation may be that clinically unresponsive
patients have tumours with clinico-pathological and biological
characteristics of aggressiveness which could cause p53 status to
become of minor importance. In particular, in our series, clinically
progressive patients were shown to be frequently older in age and
their tumours were more often poorly differentiated with respect to
other patient subgroups. Moreover, the same subpopulation had a
higher percentage of epidermal growth factor receptor positivity
(unpublished observations), which has previously been demon-
strated to negatively affect survival and response to chemotherapy
in ovarian cancer patients (Scambia et al, 1995). In addition, alter-
ations of critical molecules downstream of wild-type p53 protein
could occur, which are responsible for deregulating p53-promoted
apoptosis pathways and can influence response to treatment
(Momand et al, 1992; Michieli et al 1994; Werness et al, 1997). We
failed to find any association between p53 status and clinical
outcome in terms of time to progression and overall survival, as
reported by other authors (Marks et al 1991; Herod et al, 1996;
Reles et al, 1996). However, as summarized in Table 4, results
that were not always examined in multivariate setting are quite
conflicting, and populations included were not superimposable.
Moreover, it has to be considered that a high percentage of our
stage III–IV ovarian cancer patients were submitted to second-line
or very high-dose chemotherapy regimens which could affect
prognosis independently of p53 status. These observations could
be a reasonable explanation of the still growing controversy.
In conclusion, our study reported an interesting association
between p53 status and primary ovarian cancer cytoreduction
suggesting that the possible role of p53 in influencing successful
tumour debulking deserves further attention. The association of
p53 with response to cisplatin-based chemotherapy has also been
confirmed in multivariate analysis. Finally the need to precisely
define patient subpopulations from a clinical point of view in order
to provide a meaningful evaluation of the clinical significance of
biologic factors has been emphasized.
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